Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia

E-ISSN： 1873-5576|13|1|69-79

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.13, Iss.1, 2013-01, pp. : 69-79

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chronic Myelogenous Leukemia Guidelines

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 5, 2007-05 ,pp. : 474-474

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

New Agents in Chronic Myelogenous Leukemia

By Cortes Jorge Giles Francis

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 4, 2003-11 ,pp. : 501-512

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Substance Use and Survival after Treatment for Chronic Myelogenous Leukemia (CML) or Myelodysplastic Syndrome (MDS)

By Chang Grace Meadows Mary-Ellen Jones Jennifer A. Antin Joseph H. Orav E. John

The American Journal of Drug and Alcohol Abuse, Vol. 36, Iss. 1, 2010-01 ,pp. : 1-6

Informa Healthcare

Access to resources Recommend Favorite

Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for Treatment

Mini Reviews in Medicinal Chemistry, Vol. 4, Iss. 3, 2004-03 ,pp. : 285-299

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy of combined therapy with paclitaxel and low-level ultrasound in human chronic myelogenous leukemia cell line K562

By Yang Shuang Wang Pan Wang Xiaobing Zhang Kun Zhang Xing Liu Quanhong

Journal of Drug Targeting, Vol. 21, Iss. 9, 2013-11 ,pp. : 874-884

Informa Healthcare

Access to resources Recommend Favorite